Home > Search Results: Foà, Robin
  Search Tips
Advanced Search
Search collections:
Sort by: Display results: Output format:
Results overview: Found 3 records in 0.01 seconds.
Articles, 3 records found
Articles 3 records found  
1.
9 p, 698.5 KB Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib : A GIMEMA, ERIC and UK CLL FORUM study / Cuneo, Antonio (St. Anna University Hospital) ; Follows, George (Cambridge University Hospitals NHS Foundation Trust (Anglaterra)) ; Rigolin, Gian Matteo (St. Anna University Hospital) ; Piciocchi, Alfonso (Italian Group for Adult Hematologic Diseases (GIMEMA)) ; Tedeschi, Alessandra (Niguarda Cancer Center) ; Trentin, Livio (University of Padua) ; Perez, Angeles Medina (Hospital Costa del Sol (Marbella)) ; Coscia, Marta (University of Turin) ; Laurenti, Luca (Policlinico A. Gemelli) ; Musuraca, Gerardo (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)) ; Farina, Lucia (Fondazione IRCCS Istituto Nazionale Tumori) ; Delgado, Alfredo Rivas (Hospital Clínic i Provincial de Barcelona) ; Orlandi, Ester Maria (Fondazione IRCCS Policlinico San Matteo) ; Galieni, Piero (Ospedale C. e G. Mazzoni) ; Mauro, Francesca Romana ("Sapienza" University) ; Visco, Carlo (San Bortolo Hospital) ; Amendola, Angela (San Carlo Hospital) ; Billio, Atto (Azienda Sanitaria dell'Alto Adige) ; Marasca, Roberto (University of Modena and Reggio Emilia) ; Chiarenza, Annalisa (Azienda Universitaria Ospedaliera Policlinico Vittorio Emanuele) ; Meneghini, Vittorio (University Hospital) ; Ilariucci, Fiorella (Arcispedale S. Maria Nuova) ; Marchetti, Monia (Cardinal Massaia Hospital) ; Molica, Stefano (Azienda Ospedaliera Pugliese Ciaccio) ; Re, Francesca (University Hospital) ; Gaidano, Gianluca (Università del Piemonte Orientale Amedeo Avogadro) ; Gonzalez, Marcos (Hospital Universitari IBSAL i CIBERONC) ; Forconi, Francesco (University Hospital National Health Service Trust) ; Ciolli, Stefania (Careggi Hospital) ; Cortelezzi, Agostino (University of Milan) ; Montillo, Marco (Niguarda Cancer Center) ; Smolej, Lukas (University Hospital) ; Schuh, Anna (Oxford University Hospitals NHS Foundation Trust) ; Eyre, Toby A. (Oxford University Hospitals NHS Foundation Trust) ; Kennedy, Ben (University Hospitals of Leicester NHS Trust) ; Bowles, Kris M. (Norwich Medical School) ; Vignetti, Marco (Italian Group for Adult Hematologic Diseases (GIMEMA)) ; De La Serna, Javier (Hospital 12 de Octubre (Madrid)) ; Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ; Foà, Robin ("Sapienza" University) ; Ghia, Paolo (IRCCS San Raffaele Scientific Institute and Vita-Salute San Raffaele University) ; Universitat Autònoma de Barcelona
We performed an observational study on the efficacy of bendamustine and rituximab (BR) as first salvage regimen in chronic lymphocytic leukemia (CLL). In an intention-to-treat analysis including 237 patients, the median progression-free survival (PFS) was 25 months. [...]
2018 - 10.3324/haematol.2018.189837
Haematologica, Vol. 103 Núm. 7 (march 2018) , p. 1209-1217  
Detailed record - Creative Commons
2.
9 p, 906.5 KB Real-world use of blinatumomab in adult patients with B-cell acute lymphoblastic leukemia in clinical practice : results from the NEUF study / Boissel, Nicolas (Saint-Louis Hospital. Division of Hematology, EA3518 Saint-Louis Institute for Research) ; Chiaretti, Sabina ("Sapienza" University. Hematology Department of Translational and Precision Medicine) ; Papayannidis, Cristina (Institute of Hematology "Seràgnoli". IRCCS, Azienda Ospedaliero Universitaria di Bologna) ; Ribera, Jose-Maria (Universitat Autònoma de Barcelona. Departament de Medicina) ; Bassan, Renato (Complex Operative Unit of Hematology, dell'Angelo Hospital and Santissimi Giovanni and Paolo Hospital, Mestre and Venice, Venezia-Mestre, Italy) ; Sokolov, Andrey N. (National Research Center for Hematology, Moscow) ; Alam, Naufil (Amgen Ltd, Uxbridge, United Kingdom) ; Brescianini, Alessandra (Amgen (Europe) GmbH, Rotkreuz, Switzerland) ; Pezzani, Isabella (Amgen (Europe) GmbH, Rotkreuz, Switzerland) ; Kreuzbauer, Georg (Amgen (Europe) GmbH, Rotkreuz, Switzerland) ; Zugmaier, Gerhard (Amgen Research (Munich) GmbH, Munich, Germany) ; Foà, Robin ("Sapienza" University. Hematology Department of Translational and Precision Medicine) ; Rambaldi, Alessandro (University of Milan and Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII. Department of Oncology and Haematology)
This retrospective observational study (NEUF) included adult patients with B-cell acute lymphoblastic leukemia (B-cell ALL) who had received blinatumomab for the treatment of minimal residual disease-positive (MRD+) or relapsed/refractory (R/R) B-cell ALL via an expanded access program (EAP). [...]
2023 - 10.1038/s41408-022-00766-7
Blood Cancer Journal, Vol. 13 (january 2023)  
Detailed record - Creative Commons
3.
13 p, 2.7 MB Minimal residual disease level predicts outcome in adults with Ph-negative Bprecursor acute lymphoblastic leukemia / Gökbuget, Nicola (University Hospital of Frankfurt (Alemanya)) ; Dombret, Hervé (Hôpital Saint-Louis, Université Paris Diderot) ; Giebel, Sebastian (Maria Sklodowska Curie Memorial Cancer Center, Gliwice) ; Bruggemann, Monika (Universitätsklinikum Schleswig-Holstein (Alemanya)) ; Doubek, Michael (University Hospital Brno (República Txeca)) ; Foà, Robin (Sapienza University of Rome) ; Hoelzer, Dieter (University Hospital of Frankfurt (Alemanya)) ; Kim, Christopher (Amgen Inc, Thousand Oaks, CA, USA) ; Martinelli, Giovanni (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS) ; Parovichnikova, Elena (National Research Center for Hematology, Moscow) ; Rambaldi, Alessandro (Dipartimento di Oncologia ed Ematologia, Università degli Studi di Milano and Ospedale Papa Giovanni XXIII) ; Ribera, Jose-Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Schoonen, Marieke (Amgen Ltd, London) ; Stieglmaier, Julia M. (Amgen GmBH, Munich) ; Zugmaier, Gerhard (Amgen GmBH, Munich) ; Bassan, Renato (Ospedale dell'Angelo, Mestre-Venezia) ; Universitat Autònoma de Barcelona
Objectives: Detectable minimal residual disease (MRD) after therapy for acute lymphoblastic leukemia (ALL) is the strongest predictor of hematologic relapse. This study evaluated outcomes of patients with B-cell precursor ALL with MRD of ≥10−4. [...]
2019 - 10.1080/16078454.2019.1567654
Hematology, Vol. 24 Núm. 1 (2019) , p. 337-348  
Detailed record - Creative Commons

See also: similar author names
2 Foà, R.
Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.
UAB Digital Repository of Documents :: Search :: Submit :: Personalize :: Help
Powered by Invenio v1.1.6
Maintained by ddd.bib@uab.cat  :: Metadata license:
Working with